Cargando…

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

PURPOSE: How to factor both tumor burden and oncogenic genomic mutations as variables to predict the outcome of endocrine-based therapy (ET) in ER-positive/HER2-negative metastatic breast cancer patients (MBC) remains to be explored. METHOD: Blood samples prospectively collected from 163 ER-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Tom Wei-Wu, Hsiao, Wen, Dai, Ming-Shen, Lin, Ching-Hung, Chang, Dwan-Ying, Chen, I-Chun, Wang, Ming-Yang, Chang, Shu-Han, Huang, Shu-Min, Cheng, Ann-Lii, Wu, Ko-Wen, Tan, Kien Thiam, Lu, Yen-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460702/ https://www.ncbi.nlm.nih.gov/pubmed/37344660 http://dx.doi.org/10.1007/s10549-023-06967-3

Ejemplares similares

Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer
por: Chang, Pi-Yueh, et al.
Publicado: (2017)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

TP53, SPOP and PIK3CA Genes Status in Prostate Cancer
por: Al Zoubi, Mazhar Salim, et al.
Publicado: (2020)

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang, Dwan-Ying, et al.
Publicado: (2021)

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma
por: Wan, Huiying, et al.
Publicado: (2021)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients
por: Li, A-Jian, et al.
Publicado: (2018)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
por: Li, Guoli, et al.
Publicado: (2018)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

Mutations in TP53 and PIK3CA genes in hepatocellular carcinoma patients are associated with chronic Schistosomiasis
por: AlGabbani, Qwait
Publicado: (2022)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma
por: Liu, Shi-Yuan, et al.
Publicado: (2017)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2023)

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers
por: Yang, Libo, et al.
Publicado: (2019)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
por: Thulin, Anna, et al.
Publicado: (2021)

The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and tp53 Mutations in a Zebrafish Model
por: Wang, Shu-Ching, et al.
Publicado: (2019)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
por: Hsu, Hung-Chih, et al.
Publicado: (2019)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing
por: Bai, Xusheng, et al.
Publicado: (2014)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix
por: Tornesello, Maria Lina, et al.
Publicado: (2014)

Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer
por: Marbun, Vania Myralda Giamour, et al.
Publicado: (2022)

Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa
por: Ahmad, Hilal, et al.
Publicado: (2023)

Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy: A case report
por: Gong, Shu, et al.
Publicado: (2019)

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
por: Chen, Li, et al.
Publicado: (2018)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption
por: Ladraa, Sophia, et al.
Publicado: (2022)

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study
por: Pan, Yiqi, et al.
Publicado: (2018)

Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis
por: Lin, Xiao-Yi, et al.
Publicado: (2023)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients
por: Nteliopoulos, Georgios, et al.
Publicado: (2021)

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
por: Dave, Rajiv V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ub0s0aavb4bjusttgnijlojl5k